SSX8 anticorps (AA 21-120) (HRP)

N° du produit ABIN760610

L’anticorps Lapin Polyclonal anti-SSX8 a été validé pour WB, ELISA, IHC (fro) et IHC (p). Il convient pour détecter SSX8 dans des échantillons de Souris.

Aperçu rapide pour SSX8 anticorps (AA 21-120) (HRP) (ABIN760610)

Antigène: SSX8 (Synovial Sarcoma, X Breakpoint 8 (SSX8))

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SSX8 est conjugé à/à la HRP

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-SSX8 anticorps (HRP)

Épitope: AA 21-120

Réactivité croisée: Souris

Homologie: Human

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human SSX8

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Conseil sur la manipulation: Do NOT add Sodium Azide! Use of Sodium Azide will inhibit enzyme activity of horseradish peroxidase.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur SSX8

Antigène: SSX8 (Synovial Sarcoma, X Breakpoint 8 (SSX8))

Autre désignation: SSX8

Sujet:

Synonyms: Protein SSX8, SSX 8, SSX-8, Synovial sarcoma X breakpoint 8, SSX8_HUMAN.

Background: SSX8 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas.